Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | DAO | P14920 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | UNG | P13051 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.34 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20893878 | 0.79 | RAB9A (0.41) | SMN1; SMN2NOTUMTDP1ALDH1A1RAB9A | |
| SCHEMBL25292345 | 0.79 | TDP1 (0.42) | SMN1; SMN2NOTUMTDP1ALDH1A1RAB9A | |
| SCHEMBL25292344 | 0.79 | TDP1 (0.42) | SMN1; SMN2NOTUMTDP1ALDH1A1RAB9A | |
| SCHEMBL28760409 | 0.78 | RAB9A (0.47) | SMN1; SMN2NOTUMTDP1ALDH1A1RAB9A | |
| SCHEMBL261286 | 0.76 | ALDH1A1 (0.49) | ALDH1A1GAAPKMLMNAHPGD | |
| SCHEMBL1003723 | 0.76 | BAZ2B (0.51) | ALDH1A1GAALMNAMAPK1 | |
| SCHEMBL13658710 | 0.76 | TDP1 (0.50) | SMN1; SMN2NOTUMTDP1ALDH1A1RAB9A | |
| SCHEMBL20822006 | 0.74 | SMN1; SMN2 (0.40) | SMN1; SMN2NOTUMTDP1ALDH1A1RAB9A | |
| SCHEMBL21271446 | 0.72 | TDP1 (0.41) | SMN1; SMN2NOTUMTDP1RAB9ADAO | |
| SCHEMBL21271447 | 0.72 | TDP1 (0.41) | SMN1; SMN2NOTUMTDP1RAB9ADAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0434070-B1 | Pyrrolealdehyde derivative | MITSUBISHI CHEM CORP (JP) | 1995-08-09 | — | — | EP | claimed |
| US-11731939-B1 | Indole-based chalcone compounds as antibacterial agents | King Faisal University (SA) | 2023-08-22 | — | — | US | disclosed |
| CN-111433207-B | As alpha V Pyrrolopyrazine derivatives of integrin inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11292802-B2 | Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3707142-B1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20210163501-A1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2021-06-03 | — | — | US | disclosed |
| EP-3707142-A1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-09-16 | — | — | EP | disclosed |
| CN-111433207-A | As αVPyrrolopyrazine derivatives of integrin inhibitors | 百时美施贵宝公司 | 2020-07-17 | — | — | CN | disclosed |
| US-20160368870-A1 | OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-12-22 | — | — | US | disclosed |
| EP-2281822-A1 | New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2011-02-09 | — | — | EP | disclosed |
| US-20100197667-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7728144-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC (US) | 2010-06-01 | — | — | US | disclosed |
| US-7538132-B2 | Isoxazolo derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1893577-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| WO-2006138218-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060281740-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-12-14 | — | — | US | disclosed |
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | SUGEN, INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368870-A1 | OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY | OXER1, AK2, GPR119 | SMN1; SMN2 4397/4885NOTUM 2643/4885TDP1 4021/4885 |
| US-20210163501-A1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGB5 | SMN1; SMN2 3970/4885NOTUM 4609/4885TDP1 4048/4885 |
| US-20100197667-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM5 | SMN1; SMN2 4256/4885NOTUM 1357/4885TDP1 4518/4885 |
| US-11731939-B1 | Indole-based chalcone compounds as antibacterial agents | TPH1, TOP2B, POLB | SMN1; SMN2 4807/4885NOTUM 3385/4885TDP1 1222/4885 |
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | DMPK, MAP3K20, PHKG1 | SMN1; SMN2 2489/4885NOTUM 2806/4885TDP1 1529/4885 |
| US-11292802-B2 | Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors | ITGB1, ITGAV, ITGA1 | SMN1; SMN2 3967/4885NOTUM 4648/4885TDP1 4304/4885 |
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | CHEK2, CHEK1, ATM | SMN1; SMN2 4218/4885NOTUM 3733/4885TDP1 171/4885 |
| US-20060281740-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM3, CHRM5 | SMN1; SMN2 4256/4885NOTUM 1357/4885TDP1 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.